(Q37998451)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Raising the bar: the curative potential of human cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

Steven A Rosenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

127ps8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Structure and expression of a cloned cDNA for human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Therapeutic cancer vaccines: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Targeting p53 as a general tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003634

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22461638

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22461638

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1126/SCITRANSLMED.3003634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

PubMed publication ID

22461638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22461638%20AND%20SRC:MED&resulttype=core&format=json